

Suboptimal peak inspiratory flow rate: a noticeable risk factor for inhaler concordance in patients with chronic airway diseases

Weiwei Meng,^{1,2,3,4} Ruoyan Xiong,^{1,2,3,4} Zhiqi Zhao,^{1,2,3,4} Huihui Zeng,^{1,2,3,4} Yan Chen ^{1,2,3,4}

To cite: Meng W, Xiong R, Zhao Z, *et al*. Suboptimal peak inspiratory flow rate: a noticeable risk factor for inhaler concordance in patients with chronic airway diseases. *BMJ Open Respir Res* 2024;**11**:e001981. doi:10.1136/bmjresp-2023-001981

► Additional supplemental material is published online only. To view, please visit the journal online (<https://doi.org/10.1136/bmjresp-2023-001981>).

Received 25 July 2023
Accepted 5 April 2024



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Yan Chen;
chenyan99727@csu.edu.cn and

Huihui Zeng;
bonemarrow@csu.edu.cn

ABSTRACT

Background Inhaler concordance and the peak inspiratory flow rate (PIFR) are important determinants of treatment effects in patients with chronic airway diseases. Adequate PIFR is required for driving aerosol medication into the lower respiratory tract. However, the relationship between them has not been discussed previously. This study aimed to describe the characteristics of inhaler concordance and PIFR in Chinese patients with chronic airway diseases and discuss the associated variables and the relationship between them.

Methods In this single-centre, observational study, a total of 680 patients with chronic airway diseases were enrolled from July 2021 to April 2023. We collected data on the socio-demographic and clinical variables of inhaler concordance using the test of adherence to inhalers (TAI) and PIFR. Multivariate logistic regression was conducted to examine variables related to inhaler concordance and PIFR.

Results A total of 49.4% of patients had low concordance. Patients with chronic obstructive pulmonary disease (COPD) were more concordant than patients with asthma (mean TAI score: 43.60 vs 41.20; $p < 0.01$), while there was no difference in concordance between the asthma-COPD overlap group and the asthma or COPD group. Suboptimal PIFR (adjusted OR, 1.61; 95% CI 1.04 to 2.51) increased the risk of poor concordance among all patients, while triple therapy (adjusted OR, 0.60; 95% CI 0.35 to 0.86) reduced the risk. A total of 54.9% of patients had suboptimal PIFR. Older age, lower educational level, use of dry powder inhalers and lower forced expiratory volume in 1 s p predicted were significantly correlated with insufficient PIFR. Subgroup analysis revealed a greater proportion of patients with insufficient PIFR during exacerbation than during the stable phase (61.7% vs 43.5%, $p < 0.001$).

Conclusion Inhaler concordance was low, and suboptimal PIFR was a risk factor for poor concordance among Chinese patients with chronic airway diseases. In addition, current inhalation devices may not be suitable, and PIFR reassessment should be considered for patients with COPD during exacerbation.

Trial registration number The study was registered in [chictr.org.cn](https://www.chictr.org.cn) (ChiCTR2100052527) on 31 October 2021.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Inhaler concordance and the peak inspiratory flow rate (PIFR) are important determinants of treatment effects in patients with chronic airway diseases. Adequate PIFR is required for driving aerosol medication into the lower respiratory tract. However, the relationship between them has not been discussed previously.

WHAT THIS STUDY ADDS

⇒ Inhaler concordance was low, and suboptimal PIFR was a risk factor for poor concordance among Chinese patients with chronic airway diseases.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ This study not only provides a new perspective for clinicians when improving patients' inhaler concordance, but also provides a reminder that clinicians should pay attention to the PIFR re-evaluation and re-selection of the inhalation device for patients with chronic obstructive pulmonary disease during exacerbation.

INTRODUCTION

Chronic respiratory diseases, especially chronic obstructive pulmonary disease (COPD) and asthma, result in substantial economic and social burdens on healthcare systems worldwide, with annually increasing morbidity and mortality.¹ The China Pulmonary Health study showed that the prevalence of COPD in China was 13.7% among patients older than 40 years,² and the prevalence of asthma was 4.2% among patients older than 20 years.³ Thus, optimising the management and achieving effective control of chronic airway diseases is essential but continues to be a challenge.

It is widely known that inhalers are the pillar of treatment for chronic airway diseases, the effectiveness of which heavily depends on inhaler concordance.⁴ Nonetheless, some



epidemiological studies have indicated that poor concordance is still prevalent, which poses a major impediment to achieving optimal outcomes.^{4–6} For example, Alexopoulos *et al*⁷ reported that poor concordance led to 11.5% more exacerbations and 14.1% more hospitalisations related to COPD per year. A large Italian cohort study demonstrated that regular use of inhaled drugs led to higher survival rates among moderate-severe patients with COPD.⁸ Therefore, evaluating inhaler concordance among patients with chronic airway diseases is imperative. The test of adherence to inhalers (TAI) is a well-accepted and professional instrument for assessing patients' inhaler concordance in chronic airway diseases.⁹ Despite its good applicability in European and American populations,^{10–12} the TAI has not yet been widely used in China.

Medication concordance varies tremendously depending on demographic factors, disease-related factors, medication-related factors, etc.^{13–14} Inhalers are typically classified into three types: dry powder inhalers (DPIs), pressurised metered-dose inhalers (pMDIs) and Respimat soft mist inhalers (SMIs). The efficacy of inhalers primarily relies on the peak inspiratory flow rate (PIFR) generated by patients to overcome the inhalation device's internal resistance during a forced inspiratory manoeuvre.^{15–16} Breath-actuated DPIs require patients to generate sufficient PIFR to disaggregate and disperse the drug formulation into respirable particles. Conversely, effective drug delivery for pMDIs, which requires slow and deep inhalation, depends on a lower PIFR.¹⁷ The optimal range of the PIFR is generally considered 60–90 L/min for DPIs and 20–60 L/min for pMDIs.^{15–18–21} If a patient's PIFR does not match the prescribed inhaler, inadequate distal airway drug deposition may occur, thereby resulting in detrimental clinical consequences.²² A few studies have recently revealed that suboptimal PIFR may increase the risk of all-cause and COPD-related hospital readmissions among patients with COPD.²³

Although some European, North and South American studies have assessed inhaler concordance and PIFR in patients with COPD or asthma, little is known about patients with asthma-COPD overlap (ACO). In this study, we aimed to describe the characteristics of inhaler concordance and PIFR in Chinese patients with chronic airway diseases and discuss the potential risk factors for poor concordance, especially whether PIFR affects inhaler concordance.

METHODS

Study design, setting and participants

A single-centre observational study was performed at a 3500-bed tertiary teaching hospital, Second Xiangya Hospital of Central South University, Changsha, China. A total of 680 patients were consecutively enrolled from 1 July 2021 to 1 April 2023. The eligibility criteria included the following: (1) over 18 years of age; (2) confirmed diagnosis of COPD, asthma or ACO according to the guidelines^{24–26}; and (3) treatment with usual inhalers

for at least the previous 3 months. The exclusion criteria were as follows: (1) inability to complete the questionnaire due to severe physical or mental illness; and (2) concomitant bronchiectasis, pulmonary embolism, interstitial lung disease or other respiratory diseases.

We collected data on baseline characteristics, including age, sex, body mass index (BMI), educational level, smoking history, acute exacerbations in the previous year, years since diagnosis, medication duration, modified Medical Research Council (mMRC) dyspnoea grade and COPD Assessment Test (CAT) score (assessed at stability or during exacerbation) for patients with COPD/patients with ACO, asthma control test (ACT) score (assessed at stability or during exacerbation) for patients with asthma/patients with ACO, inhalers, inhalation devices and pulmonary function.

Exacerbations are defined as an acute worsening of respiratory symptoms that result in additional therapy. These events are classified as mild (treated with short-acting bronchodilators (SABDs) only), moderate (treated with SABDs plus antibiotics and/or oral corticosteroids) or severe (patient requires hospitalisation or visits the emergency room).²⁵

Evaluation instruments

Concordance was assessed by the 12-item TAI consisting of 10 items for patients and 2 additional items for clinicians.^{9,27} The scoring range for each of the 10 items varied from 1 (worst concordance) to 5 (best concordance), with a total sum score between 10 and 50 indicating good (50), intermediate (46–49), or poor (≤ 45) concordance. The final two items were scored as 1 or 2 for poor or good knowledge of the regimen and/or inhalation technique, respectively, with a range from 2 to 4. In addition to the concordance level, this scale also described the non-concordance pattern as follows: erratic, deliberate or unwitting.

The PIFR was assessed using an In-Check Dial (Clement Clark International, Harlow, UK) device capable of measuring inspiratory flow rates in the range of 15–120 L/min (± 10 L/min).¹⁹ In-Check Dial contains five resistance groups for DPIs classified as low (R1), medium-low (R2), medium (R3), medium-high (R4) and high (R5), whereas no resistance (R0) is set for pMDIs or SMIs. In this study, PIFR was assessed in two different ways: (1) PIFR₅ against five degrees of resistance (R1–R5), which requires fast and forceful inhalation, and (2) PIFR₀ against a resistance of zero (R0), which requires slow and gentle inhalation. Participants were then stratified into three groups: patients with optimal PIFR (60–90 L/min for DPIs or 20–60 L/min for pMDIs/SMIs), patients with excessive PIFR (>90 L/min for DPIs or >60 L/min for pMDIs/SMIs) and patients with insufficient PIFR (<60 L/min for DPIs or <20 L/min for pMDIs/SMIs) based on PIFR measurements against the resistance of the patient's current inhaler. Suboptimal PIFR is defined as excessive or insufficient PIFR. Notably, PIFR was considered

optimal for patients using multiple inhalers only when their inhalation capacity fell within the ranges for all inhalers.²⁸

Researchers orally taught patients about inhaler techniques and correct breathing manoeuvres. The PIFR was measured under the guidance of researchers.¹⁵ For patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), the PIFR was measured within 1–3 days of the onset of exacerbation and once again at a stable status.²⁹ The PIFR at each resistance was measured consecutively three times, and the maximum was recorded.

Statistical analysis

Descriptive statistical analysis of socio-demographic and clinical characteristics was performed, and categorical variables are presented as counts (n) with percentages (%) and continuous variables are presented as the means with SDs when normally distributed or as the medians with IQRs otherwise. Qualitative variables were compared using a χ^2 test or Fisher's exact test, while quantitative variables were analysed using Student's t-test, analysis of variance, or the Mann-Whitney U test.

Covariates included age, sex, BMI, educational level, smoking status, disease diagnosis, ACT score or CAT score, medication, inhalation device and PIFR. Bivariate analyses were conducted to select covariates with $p < 0.05$, and then we included these significant covariates in the multivariate regression to determine risk factors associated with poor concordance and insufficient PIFR. Data analyses were performed using IBM SPSS Statistics V.25.0. P values were two-tailed, and statistical significance was set at 0.05.

RESULTS

Characteristics of the sample

Among 680 patients (mean (SD) age 62.54 (11.43) years, 80.7% men, mean (SD) BMI 22.26 (3.43) kg/m²), 452 (66.5%) were diagnosed with COPD, 151 (22.2%) with asthma and 77 (11.3%) with ACO (online supplemental figure S1). The median (IQR) exacerbation in the past year was 1.00 (0.00–2.00) for all patients, and the median (IQR) forced expiratory volume in 1 s % (FEV₁%) predicted was 49.05 (32.52–72.50). Compared with patients with COPD and patients with ACO, patients with asthma had a significantly greater percentage of women, a greater percentage of younger individuals, a lower proportion of smokers, fewer exacerbations in the past year and better lung function (table 1). Despite the similarities in most baseline characteristics between the two groups, patients with ACO were younger than patients with COPD.

Medication concordance for chronic airway diseases

Overall, 49.4% of patients presented poor concordance to inhalers. Patients with COPD were more concordant than patients with asthma (mean TAI-10 score: 43.60 vs

41.20; $p < 0.01$, table 2). The concordance level was not significantly different between the ACO group and the COPD (43.29 vs 43.60, $p = 0.148$, table 2) or asthma (43.29 vs 41.20, $p = 0.518$, table 2) group. In addition, the pattern of non-concordance was more frequently erratic and deliberate in patients with asthma than in patients with COPD and patients with ACO ($p < 0.001$), whereas there was no significant difference in the unwitting behaviour among the three groups.

Measured peak inspiratory flow rate

Finally, 532 participants completed the PIFR tests (online supplemental figure S1). The PIFR values among patients with COPD were lower than those among patients with asthma and patients with ACO regardless of resistance (table 3). A significantly greater proportion of patients with COPD had insufficient PIFR than did patients with asthma (38.5% vs 22.1%, $p < 0.01$, table 3) and patients with ACO (38.5% vs 22.2%, $p < 0.01$, table 3).

The results showed that PIFR was prone to be insufficient in Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages 3 and 4 versus GOLD stages 1 and 2 (51.6% vs 29.9%, $p < 0.05$, online supplemental figure S2A) and in groups C and D versus groups A and B (51.5% vs 35.1%, $p < 0.05$, online supplemental figure S2A) among patients with COPD. Moreover, patients with COPD had a greater percentage of optimal PIFR in groups A and B than in groups C and D (50.0% vs 36.8%, $p < 0.05$, online supplemental figure S2A). In addition, we observed significantly lower PIFRs at any resistance and a greater percentage of insufficient PIFR among patients with COPD during acute exacerbation than among patients with COPD during the stable phase (61.7% vs 43.5%, $p < 0.001$, online supplemental figure S2B and table S1 and table S1). However, there were no significant differences in the subgroup analyses of patients with asthma (online supplemental figure S2C). Subgroup analyses of patients with ACO revealed that the patients with GOLD stages 3 and 4 versus GOLD stages 1 and 2 had a greater proportion of insufficient PIFR (43.8% vs 0.0%, $p < 0.05$, online supplemental figure S2D).

Risk factors for poor concordance

Table 4 shows the results of a logistic regression analysis of factors that were independently associated with poor concordance among all studied patients and three disease subgroups. Univariable factors, such as lower educational level, short treatment time, mono-/dual combination therapy, the use of multiple inhalation devices at one time and suboptimal PIFR, were found to be significantly related to poor concordance among patients with COPD. As indicated by the analysis of the total sample, multivariate analysis revealed that patients with COPD with suboptimal PIFR were more at risk of poor concordance than those with optimal PIFR (adjusted OR, 1.93; 95% CI 1.12 to 3.31, table 4). Rather than mono-/dual combination therapy, patients receiving triple therapy had

Table 1 Baseline characteristics of the study population and disease subgroups

| Variables | Total (n=680) | COPD group (n=452) | Asthma group (n=151) | ACO group (n=77) | P value |
|---------------------------------------|---------------------|---------------------|-----------------------|-----------------------|---------|
| Age (years)* | 62.54±11.43 | 66.61±7.94 | 51.01±13.66† | 61.25±7.85*‡ | <0.001 |
| Sex, male | 549 (80.7) | 423 (93.6) | 58 (38.4)† | 68 (88.3)‡ | <0.001 |
| Body mass index (kg/m ²)* | 22.26±3.43 | 21.84±3.29 | 23.42±3.39† | 22.46±3.83 | <0.05 |
| Educational level | | | | | <0.001 |
| Primary | 220 (32.4) | 172 (38.1) | 24 (15.9)† | 24 (31.2)‡ | – |
| Secondary | 232 (34.1) | 146 (32.3) | 60 (39.7) | 26 (33.8) | – |
| High school | 121 (17.8) | 78 (17.3) | 23 (15.2) | 20 (26.0) | – |
| University and above | 107 (15.7) | 56 (12.3) | 44 (29.2)† | 7 (9.0)‡ | – |
| Smoking index (pack-years) | 35.00 (0.00–50.00) | 40.00 (30.00–60.00) | 0.00 (0.00–0.00)† | 30.00 (10.00–49.00)*‡ | <0.05 |
| Smoking status | | | | | <0.001 |
| Current smoker | 145 (21.4) | 110 (24.3) | 13 (8.6)† | 22 (28.6)‡ | – |
| Ex-smoker | 358 (52.6) | 295 (65.3) | 22 (14.6)† | 41 (53.2)‡ | – |
| Never smoker | 177 (26.0) | 47 (10.4) | 116 (76.8)† | 14 (18.2)‡ | – |
| Years since diagnosis | 4.00 (2.00–7.00) | 4.00 (2.00–7.00) | 4.50 (1.00–10.00) | 4.50 (3.00–7.00) | 0.570 |
| Exacerbations in the previous year | 1.00 (0.00–2.00) | 1.00 (0.00–3.00) | 1.00 (0.00–1.00)† | 1.00 (0.00–3.00)‡ | <0.001 |
| Medication time (years) | 2.35 (1.00–5.00) | 3.00 (1.00–5.00) | 1.30 (0.41–3.00) | 3.00 (1.00–5.00) | <0.001 |
| CAT score* | – | 18.90±6.21 | – | 17.94±5.92 | 0.204 |
| mMRC dyspnoea grade | – | 2.00 (2.00–3.00) | – | 2.00 (1.00–3.00) | 0.119 |
| ACT score | – | – | 20.00 (18.00–22.00) | 19.00 (16.00–21.00) | <0.01 |
| Medication | | | | | <0.001 |
| LAMA | 66 (9.7) | 59 (13.0) | 3 (2.0)† | 4 (5.2) | – |
| ICS+LABA | 301 (44.3) | 137 (30.3) | 135 (89.4)† | 29 (37.7)‡ | – |
| LABA+LABA | 92 (13.5) | 88 (19.5) | 0 (0.0)† | 4 (5.2)*‡ | – |
| ICS+LABA+LABA | 221 (32.5) | 168 (37.2) | 13 (8.6)† | 40 (51.9)‡ | – |
| Inhalation device | | | | | <0.001 |
| DPIs | 479 (70.4) | 305 (67.5) | 135 (89.4)† | 39 (50.6)*‡ | – |
| pMDIs/SMIs | 86 (12.7) | 64 (14.2) | 7 (4.6)† | 15 (19.5)‡ | – |
| DPI+DPI/SMI | 115 (16.9) | 83 (18.3) | 9 (6.0)† | 23 (29.9)‡ | – |
| Lung function | | | | | – |
| Post-BD FEV ₁ % predicted | 49.05 (32.52–72.50) | 39.50 (28.00–55.60) | 88.45 (73.17–100.92)† | 50.85 (33.87–65.15)*‡ | <0.001 |
| Post-BD FEV ₁ /FVC (%) | 44.32 (33.82–60.14) | 38.62 (31.24–49.07) | 74.17 (64.46–79.56)† | 44.00 (34.29–54.33)‡ | <0.001 |

Continued

| Table 1 Continued | | | | | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|--------------------|----------------------|------------------|---------|
| Variables | Total (n=680) | COPD group (n=452) | Asthma group (n=151) | ACO group (n=77) | P value |
| Data are presented as n (%) or medians (IQRs) unless otherwise stated. | | | | | |
| *Data are presented as mean±SD. | | | | | |
| †Compared with the COPD group. | | | | | |
| ‡Compared with the asthma group. | | | | | |
| ACO, asthma-COPD overlap; ACT, asthma control test; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; DPIs, dry powder inhalers; FEV ₁ , forced expiratory volume in 1 s; FVC, forced vital capacity; ICS, inhaled corticosteroids; LABA, long-acting beta-adrenoceptor agonist; LAMA, long-acting muscarinic receptor antagonist; mMRC, modified Medical Research Council; pMDIs, pressurised metred-dose inhalers; Post-BD, postbronchodilator; SMI, Respimat soft mist inhalers. | | | | | |

significantly lower odds of poor concordance (adjusted OR, 0.47; 95% CI 0.27 to 0.80, [table 4](#)). Notably, patients with asthma with lower ACT scores were prone to be less concordant (adjusted OR, 0.82; 95% CI 0.70 to 0.95, [table 4](#)), and patients with ACO with higher CAT scores were more likely to have poor concordance (adjusted OR, 1.13; 95% CI 1.01 to 1.26, [table 4](#)).

Risk factors for insufficient PIFR

Univariate analysis revealed significant differences in age, BMI, educational level, smoking status, history of severe exacerbations in the previous year, asthma, inhalation devices, number of inhalers, exacerbation or stable status and FEV₁% predicted between the insufficient and sufficient groups in the total population. Multivariate analysis demonstrated that a higher educational level and the use of pMDIs/SMIs were protective factors (adjusted OR, 0.54; 95% CI 0.28 to 1.01 and adjusted OR, 0.15; 95% CI 0.04 to 0.55, respectively, [table 5](#)), whereas older age was a risk factor for insufficient PIFR (adjusted OR, 1.05; 95% CI 1.01 to 1.08, [table 5](#)). Subjects with a lower FEV₁% predicted had an increased risk of insufficient PIFR (adjusted OR, 0.97; 95% CI 0.96 to 0.99, [table 5](#)).

For patients with COPD, the results indicated that lower educational levels, use of DPIs, a history of severe exacerbations in the previous year and a lower FEV₁% predicted increased risk of insufficient PIFR ([table 5](#)). Further subgroup analyses revealed that the use of DPIs, groups C and D (adjusted OR, 3.89; 95% CI 1.05 to 14.46, online supplemental table S2) and a lower FEV₁% predicted were independent predictors of insufficient PIFR in patients with COPD during exacerbation. Insufficient PIFR in patients with asthma was associated with older age (adjusted OR, 1.10; 95% CI 1.01 to 1.20, [table 5](#)) and a longer course of disease (adjusted OR, 1.12; 95% CI 1.02 to 1.24, [table 5](#)). A lower FEV₁% predicted was the only risk factor for insufficient PIFR in patients with ACO (adjusted OR, 0.85; 95% CI 0.72 to 1.00, [table 5](#)).

DISCUSSION

This study described the characteristics of inhaler concordance and PIFR in Chinese patients with chronic airway diseases. Furthermore, this study demonstrated that suboptimal PIFR was an important determinant of poor inhaler concordance among patients with chronic airway diseases. Therefore, not only lung function but also inhaler concordance and PIFR should be assessed during the management of chronic airway diseases.

In accordance with Spanish studies,³⁰ our study revealed that Chinese patients with COPD did not show an optimal proportion of good inhaler concordance, and Chinese patients with asthma were even non-concordant. Our results showed that patients with COPD were older and had worse lung function than patients with asthma, which might make patients with COPD more symptomatic and more likely to experience frequent exacerbations, thus leading them to perceive the necessity of inhalers

**Table 2** Concordance level, TAI score and non-concordance behaviour patterns in overall patient and disease subgroups

| Variable | Total (n=680) | COPD group (n=452) | Asthma group (n=151) | ACO group (n=77) | P value |
|-------------------------------|---------------|--------------------|----------------------|------------------|---------|
| Concordance level | | | | | <0.001 |
| Good-intermediate concordance | 344 (50.6) | 250 (55.3) | 54 (35.8)* | 40 (51.9) | |
| Poor concordance | 336 (49.4) | 202 (44.7) | 97 (64.2)* | 37 (48.1) | |
| Total score | 43.03±7.36 | 43.60±7.47 | 41.20±6.97* | 43.29±7.00 | <0.01 |
| Erratic | 21.25±4.31 | 21.60±4.30 | 20.11±4.10* | 21.38±4.43 | <0.01 |
| Deliberate | 21.79±3.79 | 22.00±3.78 | 21.09±3.75* | 21.91±3.83 | <0.05 |
| Unwitting | 3.42±0.65 | 3.45±0.64 | 3.32±0.65 | 3.42±0.65 | 0.167 |
| Non-concordance behaviour† | | | | | <0.001 |
| Sporadic | 455 (66.9) | 281 (62.2) | 124 (82.1)* | 50 (64.9)‡ | |
| Deliberate | 405 (59.6) | 258 (57.1) | 106 (70.2)* | 41 (53.2)‡ | |
| Unwitting | 335 (49.3) | 210 (46.4) | 87 (57.8) | 38 (49.1) | |

Data are presented as the mean±SD or numbers (%).

*Compared with the COPD group.

†More than one behaviour may be present in the same case.

‡Compared with the asthma group.

ACO, asthma-COPD overlap; COPD, chronic obstructive pulmonary disease; TAI, test of adherence to inhalers.

and adhere to treatment.³¹ Some similar characteristics may explain why the concordance level between the ACO group and the COPD group was not significantly different. Given these results, we recommend assessing inhaler concordance and strengthening disease education for Chinese patients with chronic airway diseases to avoid worsening outcomes induced by treatment interruption.

Although some studies have described the characteristics of inhaler concordance and PIFR,^{29–32} the association between them has not been discussed in previous studies. Our study revealed that a suboptimal PIFR is a significant

determinant of poor concordance among Chinese patients with chronic airway diseases, especially patients with COPD. To obtain the optimal efficacy of inhalers, inhalation must be able to generate an optimal PIFR to guarantee adequate penetration of the medication into the airways.²⁸ Conversely, patients might lose confidence and eventually give up long-term inhaled therapy due to suboptimal PIFR, resulting in a compromised treatment effect. In addition, patients with COPD receiving triple therapy had a decreased risk of poor concordance. Many studies have confirmed the potential advantages of single-inhaler triple therapy (SITT) in improving

Table 3 Distribution and level of PIFR among study patients

| Variable | Total (n=532) | COPD group (n=374) | Asthma group (n=95) | ACO group (n=63) | P value |
|-------------------|-----------------------|-----------------------|-------------------------|-------------------------|---------|
| Resistance class | | | | | |
| R0 | 120.00 (90.00–120.00) | 119.00 (85.00–120.00) | 120.00 (111.50–120.00)* | 120.00 (110.00–120.00)* | <0.001 |
| R1 | 82.00 (66.00–100.00) | 77.50 (62.00–92.00) | 100.50 (81.75–115.25)* | 90.00 (80.50–106.00)* | <0.001 |
| R2 | 74.00 (60.00–88.25) | 68.00 (56.00–81.25) | 87.50 (70.75–100.00)* | 80.00 (70.00–95.25)* | <0.001 |
| R3 | 65.00 (53.00–80.00) | 60.00 (50.00–75.00) | 79.00 (63.00–89.75)* | 74.00 (64.00–85.00)* | <0.001 |
| R4 | 64.00 (50.00–77.00) | 60.00 (48.00–72.00) | 78.00 (60.00–92.00)* | 70.00 (62.00–80.00)* | <0.001 |
| R5 | 52.00 (41.50–61.00) | 49.00 (40.00–57.50) | 60.00 (51.00–70.00)* | 55.00 (50.00–66.50)* | <0.001 |
| The level of PIFR | | | | | <0.01 |
| Insufficient | 179 (33.6) | 144 (38.5) | 21 (22.1)* | 14 (22.2)* | |
| Optimal | 240 (45.1) | 159 (42.5) | 46 (48.4) | 35 (55.6) | |
| Excessive | 113 (21.3) | 71 (19.0) | 28 (29.5) | 14 (22.2) | |

Data are presented as the medians (IQRs) or numbers (%).

*Compared with the COPD group.

†Compared with the asthma group.

ACO, asthma-COPD overlap; COPD, chronic obstructive pulmonary disease; PIFR, peak inspiratory flow rate.

Table 4 Results of the multivariate logistic regression: variables that were significantly associated with poor concordance to inhalers (test of adherence-10≤45) in the total population and disease subgroups

| Variable | Total sample (n=532) | | COPD group (n=374) | | Asthma group (n=95) | | ACO group (n=63) | |
|----------------------------------------------------------------|----------------------|-----------------------|---------------------|-----------------------|---------------------|-----------------------|----------------------|----------------------|
| | Crude OR (95% CI)‡ | Adjusted OR (95% CI) | Crude OR (95% CI)‡ | Adjusted OR (95% CI) | Crude OR (95% CI)‡ | Adjusted OR (95% CI) | Crude OR (95% CI)‡ | Adjusted OR (95% CI) |
| Sex (male vs female) | 1.66 (1.07 to 2.60) | 1.20 (0.47 to 3.03) | – | – | – | – | – | – |
| Educational level (primary vs secondary school and above) | – | – | 0.62 (0.39 to 0.98) | 0.78 (0.44 to 1.38) | – | – | – | – |
| Smoking status (smoker vs non-smoker) | 1.51 (1.01 to 2.26) | 0.92 (0.48 to 1.78) | – | – | – | – | – | – |
| Medication time (years) | 0.93 (0.88 to 0.99) | 0.96 (0.90 to 1.03) | 0.90 (0.83 to 0.97) | 0.93 (0.85 to 1.03) | – | – | – | – |
| Disease diagnosis | – | – | – | – | – | – | – | – |
| COPD | 1.00 (reference) | 1.00 (reference) | – | – | – | – | – | – |
| Asthma | 1.80 (1.15 to 2.80) | 1.26 (0.70 to 2.28) | – | – | – | – | – | – |
| ACO | 1.59 (0.87 to 2.88) | 1.99 (0.96 to 4.13) | – | – | – | – | 1.13 (1.01 to 1.26)* | 1.13 (1.01 to 1.26)* |
| CAT score | – | – | – | – | – | – | – | – |
| ACT score | – | – | – | – | 0.82 (0.70 to 0.95) | 0.82 (0.70 to 0.95)** | – | – |
| Medication (mono/ dual combination therapy vs triple therapy)† | 0.59 (0.40 to 0.85) | 0.60 (0.35 to 0.86)** | 0.59 (0.37 to 0.92) | 0.47 (0.27 to 0.80)** | – | – | – | – |
| Inhalation device (single vs multiple) | – | – | 0.56 (0.33 to 0.95) | 0.94 (0.40 to 2.20) | – | – | – | – |
| PIFR (optimal vs suboptimal)§ | 1.55 (1.00 to 2.40) | 1.61 (1.04 to 2.51)* | 1.90 (1.12 to 3.23) | 1.93 (1.12 to 3.31)* | – | – | – | – |

*P value<0.05, **P<0.01, ***P<0.001.
 †Triple therapy (ICS/LABA/LAMA) included open triple and fixed triple therapy. Monotherapy refers to LAMA. Dual therapy included ICS/LABA and LABA/LAMA.
 ‡Only patient covariates that were significant in bivariate analyses with the primary predictor of interest (p<0.05) were included in the final model.
 §Suboptimal PIFR was defined as excessive and insufficient PIFR.
 ACO, asthma-COPD overlap; ACT, asthma control test; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; LABA, long-acting beta-adrenoceptor agonist; LAMA, long-acting muscarinic receptor antagonist; PIFR, peak inspiratory flow rate.

Table 5 Results of the multivariate logistic regression: variables that were significantly associated with insufficient PIFR in the total population and disease subgroups

| Variable | Total sample (n=532) | | COPD group (n=374) | | Asthma group (n=95) | | ACO group (n=63) | |
|------------------------------------------------------------------|----------------------|-----------------------|---------------------|----------------------|---------------------|----------------------|----------------------|------------------------|
| | Crude OR (95% CI)† | Adjusted OR (95% CI) | Crude OR (95% CI)† | Adjusted OR (95% CI) | Crude OR (95% CI)† | Adjusted OR (95% CI) | Crude OR (95% CI)† | Adjusted OR (95% CI) |
| Age (years) | 1.06 (1.03 to 1.08) | 1.05 (1.01 to 1.08)* | | | 1.08 (1.01 to 1.15) | 1.10 (1.01 to 1.20)* | – | – |
| Body mass index (kg/m ²) | 0.89 (0.84 to 0.96) | 0.96 (0.87 to 1.06) | 0.87 (0.81 to 0.95) | 0.93 (0.83 to 1.04) | – | – | – | – |
| Educational level (primary vs secondary school and above) | 0.38 (0.24 to 0.61) | 0.54 (0.28 to 1.01)* | 0.37 (0.22 to 0.65) | 0.41 (0.20 to 0.85)* | 0.17 (0.04 to 0.68) | 0.61 (0.11 to 3.43) | – | – |
| Smoking status (smoker vs non-smoker) | 0.58 (0.34 to 1.00) | 2.44 (1.05 to 5.70) | – | – | – | – | – | – |
| The history of severe exacerbations in the past year (no vs yes) | 2.43 (1.54 to 3.83) | 1.60 (0.84 to 3.03) | 2.15 (1.26 to 3.66) | 2.10 (1.03 to 4.32)* | – | – | – | – |
| Years since diagnosis | – | – | – | – | 1.10 (1.01 to 1.18) | 1.12 (1.02 to 1.24)* | – | – |
| Disease diagnosis | – | – | – | – | – | – | – | – |
| COPD | 1.00 (reference) | 1.00 (reference) | | | | | | |
| Asthma | 0.26 (0.13 to 0.52) | 0.50 (0.12 to 2.03) | | | | | | |
| ACO | 0.50 (0.24 to 1.06) | 0.40 (0.15 to 1.09) | | | | | | |
| CAT score | – | – | 1.05 (1.01 to 1.10) | 0.99 (0.93 to 1.07) | – | – | – | – |
| mMRC dyspnoea grade | – | – | 1.58 (1.19 to 2.11) | 1.40 (0.95 to 2.07) | – | – | – | – |
| Inhalation device (DPIs† vs pMDIs/SMI) | 0.12 (0.03 to 0.40) | 0.15 (0.04 to 0.55)** | 0.14 (0.04 to 0.47) | 0.18 (0.05 to 0.67)* | – | – | – | – |
| Inhalation device (single vs multiple) | 2.67 (1.56 to 4.57) | 1.77 (0.84 to 3.74) | – | – | – | – | 6.13 (1.33 to 28.20) | 18.74 (0.74 to 475.10) |

Continued

Table 5 Continued

| Variable | Total sample (n=532) | | COPD group (n=374) | | Asthma group (n=95) | | ACO group (n=63) | |
|---------------------------------|----------------------|------------------------|---------------------|----------------------|---------------------|----------------------|---------------------|----------------------|
| | Crude OR (95% CI)† | Adjusted OR (95% CI) | Crude OR (95% CI)† | Adjusted OR (95% CI) | Crude OR (95% CI)† | Adjusted OR (95% CI) | Crude OR (95% CI)† | Adjusted OR (95% CI) |
| FEV ₁ % predicted | 0.97 (0.96 to 0.99) | 0.97 (0.96 to 0.99)*** | 0.97 (0.96 to 0.99) | 0.98 (0.96 to 1.00)* | - | - | 0.89 (0.81 to 0.98) | 0.85 (0.72 to 1.00)* |
| stable vs exacerbation | 3.41 (2.14 to 5.43) | 1.35 (0.62 to 2.96) | 2.63 (1.54 to 4.50) | 1.18 (0.53 to 2.65) | - | - | - | - |
| GOLD group (A and B vs C and D) | - | - | 1.96 (1.14 to 3.37) | 0.65 (0.10 to 4.20) | - | - | - | - |

*P value<0.05, **P<0.01, ***P<0.001.
†DPIs, DPIs+DPIs and DPIs+SMDs were included.
‡Only patient covariates that were significant in bivariate analyses with the primary predictor of interest (p<0.05) were included in the final model.
ACO, asthma-COPD overlap; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; DPIs, dry powder inhalers; FEV₁, forced expiratory volume in 1 s; GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, modified Medical Research Council; PIFR, peak inspiratory flow rate; pMDIs, pressurised metered-dose inhalers; SMDs, RespiMat soft mist inhalers.

inhaler concordance and persistence compared with the use of multiple inhalers.^{33–36} Combined with the findings of previous studies, our results may be explained by the high percentage of patients who developed better outcomes with SITT than with mono-/dual combination therapy.³⁷ Accordingly, healthcare professionals should pay more attention to follow-up and concordance assessment among patients with COPD with suboptimal PIFR and mono/dual combination therapy.

Overall, 54.9% of patients exhibited suboptimal PIFR, suggesting that many patients cannot generate appropriate PIFR, which might lead to treatment failure. Multivariate regression analysis revealed that four independent variables including older age, lower educational level, use of DPIs and lower FEV₁% predicted were associated with insufficient PIFR in all patients. The PIFR is inversely correlated with the internal resistance of inhalation devices.^{15 20} DPIs have greater resistance than pMDIs (no resistance) and are prone to result in lower and even insufficient PIFR. Although there was no linear relationship between the PIFR and FEV₁,^{18 29} our study observed a greater proportion of insufficient PIFR in patients with lower FEV₁% predicted. These results suggested that healthcare professionals should assess PIFR in Chinese patients with chronic airway diseases, especially in older patients with lower educational levels, worse lung function and use of DPIs.

Not only educational level, inhalation devices and FEV₁% predicted but also the history of severe exacerbations in the past year was an important predictor of insufficient PIFR in patients with COPD. This may be because inspiratory muscle strength has difficulty completely recovering to a normal degree after serious exacerbations of COPD, leading to insufficient PIFR.^{38 39} In addition, our study indicated that patients with COPD presented a greater proportion of insufficient PIFR than did patients with asthma and patients with ACO, which might be attributed to older age, worse lung function and severe air trapping among patients with COPD.^{28 40 41} These results demonstrated that it might be more difficult for patients with COPD to overcome internal resistance to inhalation devices and thus obtain unsatisfactory and ineffective treatment outcomes.

One previous study assessed the difference in PIFR between patients with AECOPD and patients with COPD with stable status and indicated no significant difference between the two groups.²⁹ However, our study revealed that the PIFRs of patients with COPD were lower during acute exacerbation than during a stable status. This contradiction may be due to the different study populations and the heterogeneity of people. The former is a comparison of two groups of people with different states, while the latter is a comparison of different states in a group of people. In addition, there was a larger sample size and a higher proportion of patients in GOLD stages 3 and 4 (58.8%) in our study. Due to hyperinflation and hypoxaemia, respiratory muscles are more fatigued and muscle function is often more compromised in



patients with AECOPD than in patients with COPD with a stable status,¹⁹ resulting in a lower PIFR in patients with AECOPD. Deteriorative PIFR due to AECOPD might not satisfy the requirements of current inhalation devices and lead to ineffective inhaled therapy. In addition, multivariate regression analysis revealed that the use of DPIs and a lower FEV₁% predicted were independent predictors of insufficient PIFR in patients with AECOPD. Therefore, we suggest that patients with AECOPD, especially those with worse lung function and those in groups C and D, should receive a PIFR assessment to determine the optimal inhalation device during exacerbation. On the other hand, nebulisation may rapidly and effectively alleviate symptoms in patients who are unable to measure PIFR for various reasons during exacerbation and therefore cannot determine their optimal inhalation device.^{23 42}

Similar to previous studies,⁴³ our results showed that the PIFR was negatively associated with age and years since diagnosis among patients with asthma. For patients with ACO, a lower FEV₁% predicted was the only and strongest determinant of insufficient PIFR. Accordingly, caution should be taken among older patients with asthma with a longer course of disease and patients with ACO with GOLD stages 3 and 4 because they may benefit more from PIFR-optimisation of inhaler choice. It should be noted that the sample sizes in the exacerbation group and GOLD stages 3 and 4 groups of patients with asthma were too small to compare the difference in the PIFR between each asthma subgroup. Similarly, despite a higher percentage of insufficient PIFR in the exacerbation group than in the stable group among patients with ACO, the difference was not statistically significant, which might be due to the small sample size.

There were some limitations in this study. First, the main limitation was utilisation of self-reported questionnaire to assess inhaler concordance. The authors considered that using a self-reported questionnaire was the better option for study design and aim since it is simple and flexible for clinicians, although it can under-report non-concordance. In the corresponding literature, there is an abundance of concordance questionnaires, however, in our study, the chosen questionnaire was TAI because of its specialisation in chronic airway diseases. Further studies should combine self-reports with objective measurements of concordance (eg, prescription refills) to determine inhaler concordance. Furthermore, a larger sample size is needed to observe the characteristics in subgroups of patients with asthma and patients with ACO. In addition, we will determine whether PIFR-optimisation of inhaler choice can improve clinical outcomes in a future prospective study.

CONCLUSIONS

Our study revealed that patients' inhaler concordance was low and that suboptimal PIFR was a noticeable risk factor for poor concordance among Chinese patients

with chronic airway diseases. To improve inhaler concordance and clinical outcomes, PIFR assessment could be performed for patients with chronic airway diseases, especially for those at high risk of insufficient PIFR. In addition, the PIFR should be assessed in patients with AECOPD to choose an appropriate inhalation device.

Author affiliations

¹Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China

²Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, China

³Clinical Medical Research Center for Pulmonary and Critical Care Medicine in Hunan Province, Changsha, China

⁴Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, China

Contributors WM wrote the manuscript. WM and HZ participated in the data analysis. WM, ZZ and RX participated in the data collection. WM, ZZ, RX, HZ and YC contributed to the discussion, and HZ and YC reviewed and edited the manuscript. All authors read and approved the final manuscript. YC is the guarantor of this work.

Funding This work was supported by the National Natural Science Foundation of China (82070049) and the Bethune Charitable Foundation (BJ-RW2020011J).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Consent obtained directly from patient(s).

Ethics approval This study was approved by the Ethics Committee of the Second Xiangya Hospital of Central South University (LYF2021155). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Yan Chen <http://orcid.org/0000-0002-7713-6913>

REFERENCES

- Rabe KF, Watz H. Chronic obstructive pulmonary disease. *Lancet* 2017;389:1931–40.
- Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China pulmonary health [CPH] study): a national cross-sectional study. *Lancet* 2018;391:1706–17.
- Huang K, Yang T, Xu J, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. *Lancet* 2019;394:407–18.
- Chrystyn H, Audibert R, Keller M, et al. Real-life Inhaler adherence and technique: time to get smarter. *Respir Med* 2019;158:24–32.
- Mäkelä MJ, Backer V, Hedegaard M, et al. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. *Respir Med* 2013;107:1481–90.
- López-Campos JL, Quintana Gallego E, Carrasco Hernández L. Status of and strategies for improving adherence to COPD treatment. *Int J Chron Obstruct Pulmon Dis* 2019;14:1503–15.

- 7 Alexopoulos EC, Malli F, Mitsiki E, *et al.* Frequency and risk factors of COPD exacerbations and hospitalizations: a nationwide study in Greece (Greek obstructive lung disease epidemiology and health economics: GOLDEN study). *Int J Chron Obstruct Pulmon Dis* 2015;10:2665–74.
- 8 Belleudi V, Di Martino M, Cascini S, *et al.* The impact of adherence to inhaled drugs on 5-year survival in COPD patients: a time dependent approach. *Pharmacoepidemiol Drug Saf* 2016;25:1295–304.
- 9 Plaza V, López-Viña A, Cosío BG, *et al.* Test of adherence to inhalers. *Arch Bronconeumol* 2017;53:360–1.
- 10 Khosravi S, Rafiei F, Norozy M, *et al.* Cross-cultural adaptation of the Persian version of test of the adherence to Inhalers (TAI). *Patient Prefer Adherence* 2019;13:1693–9.
- 11 Muneshwarao J, Hassali MA, Ibrahim B, *et al.* Translation and validation of the test of adherence to Inhalers (TAI) questionnaire among adult patients with asthma in Malaysia. *J Asthma* 2021;58:1229–36.
- 12 Baiardini I, Paoletti G, Malipiero G, *et al.* Validation of the Italian version of the test of adherence to inhalers. *J Investig Allergol Clin Immunol* 2020;30:450–2.
- 13 Brown MT, Bussell J, Dutta S, *et al.* Medication adherence: truth and consequences. *Am J Med Sci* 2016;351:387–99.
- 14 Brown MT, Bussell JK. Medication adherence: WHO cares? *Mayo Clin Proc* 2011;86:304–14.
- 15 Haughney J, Lee AJ, McKnight E, *et al.* Peak Inspiratory flow measured at different inhaler resistances in patients with asthma. *J Allergy Clin Immunol Pract* 2021;9:890–6.
- 16 Ghosh S, Ohar JA, Drummond MB. Peak inspiratory flow rate in chronic obstructive pulmonary disease: implications for dry powder inhalers. *J Aerosol Med Pulm Drug Deliv* 2017;30:381–7.
- 17 Ghosh S, Pleasants RA, Ohar JA, *et al.* Prevalence and factors associated with suboptimal peak Inspiratory flow rates in COPD. *Int J Chron Obstruct Pulmon Dis* 2019;14:585–95.
- 18 Chen S-Y, Huang C-K, Peng H-C, *et al.* Inappropriate peak inspiratory flow rate with dry powder Inhaler in chronic obstructive pulmonary disease. *Sci Rep* 2020;10:7271.
- 19 van der Palen J. Peak Inspiratory flow through Diskus and Turbuhaler, measured by means of a peak Inspiratory flow meter (in-check DIAL). *Respir Med* 2003;97:285–9.
- 20 Chen S-Y, Huang C-K, Peng H-C, *et al.* Peak-inspiratory-flow-rate guided inhalation therapy reduce severe exacerbation of COPD. *Front Pharmacol* 2021;12:704316.
- 21 Sharma G, Mahler DA, Mayorga VM, *et al.* Prevalence of low peak Inspiratory flow rate at discharge in patients hospitalized for COPD exacerbation. *Chronic Obstr Pulm Dis* 2017;4:217–24.
- 22 Leving M, Wouters H, de la Hoz A, *et al.* Impact of PIF, inhalation technique and medication adherence on health status and exacerbations in COPD: protocol of a real-world observational study (Pifotal COPD study). *Pulm Ther* 2021;7:591–606.
- 23 Loh CH, Peters SP, Lovings TM, *et al.* Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all-cause readmissions. *Ann Am Thorac Soc* 2017;14:1305–11.
- 24 Asthma Gif. Global strategy for asthma management and prevention. 2021.
- 25 Committee GE. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2021. Available: <https://goldcopd.org/> [accessed 22 Nov 2020]
- 26 Milne S, Mannino D, Sin DD. Asthma-COPD overlap and chronic airflow obstruction: definitions, management, and unanswered questions. *J Allergy Clin Immunol Pract* 2020;8:483–95.
- 27 Meng WW, Cui YN, Luo LJ, *et al.* Reliability and validity of the Chinese version of the test of the adherence to inhalers (TAI). *Zhonghua Jie He He Hu Xi Za Zhi* 2022;45:423–30.
- 28 Represas-Represas C, Aballe-Santos L, Fernández-García A, *et al.* Evaluation of suboptimal peak Inspiratory flow in patients with stable COPD. *J Clin Med* 2020;9:3949.
- 29 Hua J-L, Ye X-F, Du C-L, *et al.* Optimizing inhalation therapy in the aspect of peak inhalation flow rate in patients with chronic obstructive pulmonary disease or asthma. *BMC Pulm Med* 2021;21:302.
- 30 Plaza V, López-Viña A, Entrenas LM, *et al.* Differences in adherence and non-adherence behaviour patterns to Inhaler devices between COPD and asthma patients. *COPD* 2016;13:547–54.
- 31 Janssens W, Vandenberghe P, Hardeman E, *et al.* Inspiratory flow rates at different levels of resistance in elderly COPD patients. *Eur Respir J* 2008;31:78–83.
- 32 Ding N, Zhang W, Wang Z, *et al.* Prevalence and associated factors of suboptimal daily peak Inspiratory flow and technique misuse of dry powder Inhalers in outpatients with stable chronic airway diseases. *Int J Chron Obstruct Pulmon Dis* 2021;16:1913–24.
- 33 Miravittles M, Marín A, Huerta A, *et al.* Estimation of the clinical and economic impact of an improvement in adherence based on the use of once-daily single-inhaler triple therapy in patients with COPD. *Int J Chron Obstruct Pulmon Dis* 2020;15:1643–54.
- 34 Zhang S, King D, Rosen VM, *et al.* Impact of single combination Inhaler versus multiple Inhalers to deliver the same medications for patients with asthma or COPD: a systematic literature review. *Int J Chron Obstruct Pulmon Dis* 2020;15:417–38.
- 35 Bogart M, Stanford RH, Laliberté F, *et al.* Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. *Int J Chron Obstruct Pulmon Dis* 2019;14:343–52.
- 36 Lipson DA, Barnhart F, Brealey N, *et al.* Once-daily single-Inhaler triple versus dual therapy in patients with COPD. *N Engl J Med* 2018;378:1671–80.
- 37 Lipson DA, Barnacle H, Birk R, *et al.* FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2017;196:438–46.
- 38 Samarghandi A, Ioachimescu OC, Qayyum R. Association between peak Inspiratory flow rate and hand grip muscle strength in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease. *PLoS One* 2020;15:e0227737.
- 39 Basso-Vanelli RP, Di Lorenzo VAP, Labadessa IG, *et al.* Effects of Inspiratory muscle training and calisthenics-and-breathing exercises in COPD with and without respiratory muscle weakness. *Respir Care* 2016;61:50–60.
- 40 Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak Inspiratory flow rate against the simulated resistance of the Diskus® dry powder Inhaler. *J Aerosol Med Pulm Drug Deliv* 2013;26:174–9.
- 41 Duarte AG, Tung L, Zhang W, *et al.* Spirometry measurement of peak Inspiratory flow identifies suboptimal use of dry powder Inhalers in ambulatory patients with COPD. *Chronic Obstr Pulm Dis* 2019;6:246–55.
- 42 Chen Y, Liu Y, Zhang J, *et al.* Comparison of the clinical outcomes between Nebulized and systemic corticosteroids in the treatment of acute exacerbation of COPD in China (CONTAIN study): a post hoc analysis. *Int J Chron Obstruct Pulmon Dis* 2020;15:2343–53.
- 43 Kawamatawong T, Khiawwan S, Pornsuriyasak P. Peak inspiratory flow rate measurement by using in-check DIAL for the different Inhaler devices in elderly with obstructive airway diseases. *J Asthma Allergy* 2017;10:17–21.